UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 91.8%

Neg 91.8% Neu 0% Pos 0%

UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers the price target from $57 to $15.